Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples